Type: Product
Name: Gleevec
First reported Oct 17 2014 - Updated Oct 17 2014 - 5 reports

NICE swayed by long term Glivec data

NICE has reversed a long-standing block on using Glivec in GIST tumours, saying new evidence has persuaded it to change its mind.Final draft guidance published today proposes to recommend Novartis' Glivec (imatinib) for up to three years for peo...Related ... [Published BioPortfolio - Oct 17 2014]
First reported Oct 14 2014 - Updated Oct 15 2014 - 1 reports

ARIAD's Iclusig Gains Positive Recommendation from PRAC

Sometimes, drugs marketed by pharma/biotech companies are required to be assessed by regulatory agencies to determine the risks associated with the use of the drug. In the EU, the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee ... [Published - Oct 14 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Access to good therapy is big issue for patients in poorer nations

Pharma companies will have to change their approach if the demand for affordable cancer drugs in poor countries is to be met.(Keystone)When Dr Mohga Kamal-Yanni spent a month in her native Egypt over the summer, she was struck by both the rising demand ... [Published Swiss Info - Oct 14 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

Chemotherapy is brutal, but targeted drugs can reduce collateral damage

By using a targeted drug doctors can reduce the dosage of chemotherapy, improving patients’ quality of life. Photograph: Christopher Thomond/GuardianWhen I first studied cancer medicine as an undergraduate, my lecturer described chemotherapy as “beating ... [Published - Oct 09 2014]
First reported Oct 06 2014 - Updated Oct 07 2014 - 1 reports

60 Minutes Just Attacked High Drug Prices. Here's What You Should Know

60 Minutes , the most successful news program in American history, just took aim at the extraordinarily high ($100,000 per patient per year) prices charged for cancer drugs. The pharmaceutical industry, which only provided canned statements and badly ... [Published - Oct 06 2014]
First reported Oct 06 2014 - Updated Oct 06 2014 - 1 reports

Nat’l oncologists group tackles spiraling drug costs

Dr. Richard Schilsky of the American Society of Clinical Oncology discusses the high price of Gleevec, a leukemia wonder drug. ... [Published CBS News - Oct 06 2014]
First reported Oct 03 2014 - Updated Oct 03 2014 - 1 reports

United in cause, spirit

Carrying the Relay For Life banner along with friend Sheila Martin (not pictured) Friday Harbor’s Ruthe Ramirez leads the “Survivor’s Walk” procession at the annual fundraiser.— image credit: Journal photo / Scott RasmussenBreakthroughs come along every ... [Published - Oct 03 2014]
First reported Oct 02 2014 - Updated Oct 02 2014 - 1 reports

Pharmaceutical companies refute Congress' post claiming hike in prices of life-saving drugs

B y Divya RajagopalMUMBAI: A post on the Congress party's website claiming steep hikes in the prices of life-saving medicines, especially cancer drug Glivec, has led to the social media playing it up and also creating confusion.Novartis, which owns the ... [Published Economic Times - Oct 02 2014]
First reported Sep 28 2014 - Updated Sep 28 2014 - 1 reports

Purchase Gleevec For Saturday Delivery, Online Cod Gleevec Overnight Delivery

Purchase gleevec for saturday delivery, online cod gleevec overnight deliveryMed Portal has proved its reliability and safety, working at pharmaceutical market since 2003. One of the most urgent problems in online pharmacy business is the quality of the ... [Published Student Village - Sep 28 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

Charts of the day: Higher prices for the same product

An article in Business Insider has rounded up several charts that show what’s wrong with the U.S. health care system. Not surprisingly, a familiar issue made the list: the exceptionally high costs of lifesaving prescription drugs.As you can see in the ... [Published Ahip Hi-Wire - Sep 24 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

MHLW Orders Insert Revisions For Glivec, Lyrica After Side-Effects

Article # 28140922013Posted: Sep. 23, 2014 1:55 AM GMTExecutive SummaryThe MHLW in Japan has instructed Novartis and Pfizer to revise the packaging inserts for the anticancer agent Glivec and pain medication Lyrica respectively after new side-effects ... [Published Health News Daily - Sep 23 2014]
First reported Sep 21 2014 - Updated Sep 21 2014 - 1 reports

Leukemia sufferers make drug plea

"With target-medication over the past decade, the disease has become much more treatable," said Kwong Yok-lam, chair professor at the University of Hong Kong's department of medicine.Glivec, a "smart" drug that targets cancer cells, has been available ... [Published Hong Kong Standard - Sep 21 2014]


...all cell and gene therapies in that it’s actually ahead of the schedule we set for ourselves when we first started treating patients," June said. "We pinch ourselves because, you know, until recently we didn’t know if we got lucky or if it would last. Our initial patients are still in remission, so we know it’s durable and reproducible. That’s something that makes us excited every day." Source The Lancet Related Itemscancer t cells b cells designer t cells
"Unlike other out of cycle reviews, this one is really focused on just on trying to build that engagement between India and the US on IP" she added
"I believe it is very important for oncologists and their staff to be aware of these out-of-pocket costs for their patients and help guide patients to all available assistance with these costs as needed" she added
...Blogs have also been spreading the rumour, adding to the confusion. "We get atat least 20 calls every day from across the country asking for the tablet."

More Content

All (138) | News (115) | Reports (0) | Blogs (23) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
NICE swayed by long term Glivec data [Published BioPortfolio - Oct 17 2014]
NICE reviews guidance on imatinib for digestive... [Published NICE - Oct 17 2014]
NICE reverses guidance on Novartis’ Glivec for ... [Published Pharma Letter - Oct 17 2014]
Novartis cancer drug beating path to NHS [Published BioPortfolio - Oct 17 2014]
Novartis cancer drug beating path to NHS [Published Pharmafocus - Oct 17 2014]
NICE backs Novartis' Glivec for GIST [Published Pharma Times - Oct 17 2014]
Lab-Made Blood Cells Hunt Cancer, Leading to Re... [Published The Verge - Oct 15 2014]
Big Pharma Cashes in on Americans Paying (Highe... [Published Drug Watch - Oct 15 2014]
ARIAD's Iclusig Gains Positive Recommendation f... [Published - Oct 14 2014]
Top 10 Most Expensive Drugs of 2013 [Published P&T Community - Oct 14 2014]
US launches review of India's Intellectual Prop... [Published Economic Times - Oct 14 2014]
Access to good therapy is big issue for patient... [Published Swiss Info - Oct 14 2014]
Novartis Releases Data on Secukinumab for Plaqu... [Published - Oct 13 2014]
Patent-Protected Oral Cancer Drugs Are Drivers ... [Published General Medicine eJournal - Oct 13 2014]
Standing on the promises: Mother of Rep. Seller... [Published Orangeburg Times and Democrat - Oct 12 2014]
MODI'S US VISIT: Introducing Bad Patents & Remo... [Published Peoples - Oct 11 2014]
Net hoax leads to clamour for cure-all cancer drug [Published Times of India - Oct 11 2014]
Patients clamour for cure-all cancer ‘wonder’ d... [Published Times of India - Oct 10 2014]
New Zealand approval of Novartis multiproduct p... [Published Pharma Letter - Oct 10 2014]
10 things your health insurance won't tell you -2- [Published - Oct 10 2014]
NOL3 is a predictor of patient outcome [Published PharmCast - Oct 10 2014]
SC to hear case against withdrawal of drug pric... [Published Economic Times - Oct 10 2014]
SC agrees on urgent hearing of drug price plea [Published Calcutta Telegraph - Oct 10 2014]
Chemotherapy is brutal, but targeted drugs can ... [Published - Oct 09 2014]
Using crystals to cure cancer [Published Noodls - Oct 08 2014]
Novartis Collaborates with Bristol-Myers Squibb [Published - Oct 07 2014]
Expert on 60 Minutes: High-Priced Cancer Drugs ... [Published Diabetes Care - Oct 06 2014]
How much would you pay for cancer drugs? Chat w... [Published Times Picayune / - Oct 06 2014]
'60 Minutes' Delivers Blow to Big Pharma over D... [Published - Oct 06 2014]
60 Minutes Just Attacked High Drug Prices. Here... [Published - Oct 06 2014]
1 2 3 4 5
In Focus
Content Volume
Document Volume


sort by: Date | Relevance
'60 Minutes' Delivers Blow to Big Pharma over D... [Published - Oct 06 2014]
60 Minutes has just produced a piece on drug pricing that is a must watch for anyone in the industry. The details of the story are somewhat old.  60 Minutes has caught up with two doctors who in 2012 told drug makers, “enough.”   In October of 2012, ...
Novartis fails to report side effects, fatality [Published PharmaGossip - Aug 30 2014]
6:52 pm, August 30, 2014 Jiji PressNovartis Pharma K.K. said it has failed to report to the health ministry at least 2,579 cases of serious side effects, including a fatality, from its drugs for leukemia and other diseases even though its employees ...
Improving the FDA, Ctd [Published The Daily Dish | By Andrew Sullivan - Aug 16 2014]
by Elizabeth Nolan Brown Should the U.S. Food and Drug Administration inch closer to Europe’s drug approval model , in which certified, independent bodies can (and compete to) review new products? A Dish reader says, hey, it worked for the Federal ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 05 2014]
Phenotypic Assays in Cancer Drug Discovery [Published In the Pipeline - Jul 24 2014]
The topic of phenotypic screening has come up around here many times, as indeed it comes up very often in drug discovery. Give your compounds to cells or to animals and look for the effect you want: what could be simpler? Well, a lot of things could, ...
1 2 3 4 5
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.